MERTK and diabetes mellitus: Results revealed that exogenous aPC treatment prevented the diabetes-induced reduction in macrophages efferocytosis and that aPC’s effect was lost in diabetic ApoE−/− mice treated with MerTK specific morpholino (Fig. 6F and Supplementary Fig. 7).